Glutamate, inflammation and psychosis; therapeutic implications and the possibility of prevention
I will review evidence that glutamate and inflammation may be involved in the pathogenesis of schizophrenia and how we are testing these possibilities using novel imaging techniques. We recently showed that the anti-inflammatory antibiotic drug minocycline when taken for a year added to treatment as usual, improved the outcome in people within 5 years of the onset of their schizophrenia. Negative symptoms seemed to be most benefitted. Minocycline has a number of actions which might be relevant to its effect including actions on glutamate function.